Technical

The Price Picture — Centene Corporation

Centene's price action says something the FY2025 income statement does not: the worst is in. Shares cratered 40% on a single July 2025 session when management pulled annual guidance, bottomed three weeks later near $25, and have spent nine months grinding back to $41.82. The 50-day SMA crossed back above the 200-day on January 30, 2026 — a fresh golden cross — and price now sits 15% above its 200-day. Momentum is hot enough to demand caution near term (RSI 69, price kissing the upper Bollinger band), but the multi-month structure has flipped from "falling knife" to "base-and-recover."

1. Price Snapshot

2. The Critical Chart — Decade Of Price Plus 50/200 SMA

Price is above the 200-day ($41.82 vs $36.25, a 15.4% premium). The lifetime view is the more important read: Centene rode Medicaid expansion and the WellCare deal to a $148 peak in 2018, traded a wide range through 2019–2022, then bled lower through 2023 and 2024 before the July 2025 cliff. What you are looking at now is the first attempt at trend repair since that crash.

The regime is best read as early uptrend off a base, not a continuation. The 200-day SMA is still sloping gently downward; price has reclaimed it but has not yet pulled the longer average up with it.

3. Relative Performance — Indexed To 100

Three years of relative performance: $100 invested in CNC in April 2023 is worth $63 today, a roughly 37% drawdown. Benchmark series (SPY, XLV) were not staged in the price feed, so a side-by-side overlay is unavailable for this run. Read against the absolute returns alone, the trend is unambiguous — multi-year underperformance versus any reasonable equity comparator, with the bounce off the July 2025 low only partially closing the gap. The 1-month +28% rally and 6-month +16% recovery suggest relative strength has stopped deteriorating; the 1-year (-33%) and 3-year (-37%) figures say the long-term gap has not yet narrowed materially.

4. Momentum — RSI And MACD

Near-term momentum is bullish but stretched. RSI ran from 14 (deep oversold) on July 21, 2025 to 81 (overbought) in early January 2026, cooled into the 50s through Q1, and has rebuilt to 69 over the last two weeks. The MACD histogram has been positive and expanding for six straight sessions. Translation: the 1-to-3 month tape favors continuation, but the next pullback can come from any session — pricing in good news has gotten ahead of fundamentals.

5. Volume And Conviction

The bounce from $25 to $42 has happened on declining volume. The 50-day average crested in July 2025 with the guidance-withdrawal dump and has decayed steadily since; recent sessions are printing at or below the 50-day average. That is a yellow flag for the rally — trends that lack volume confirmation are easier to reverse.

The three largest volume days in the entire 10-year history bracket the regime well: the July 2, 2025 collapse (13.5x average volume, -40% on guidance withdrawal), the March 27, 2019 announcement of the WellCare deal (10.6x average), and a May 2018 earnings session (9.3x average). Two of three were sell-offs.

6. Volatility Regime

30-day realized volatility is 38% — elevated, but inside the "normal" band of the last decade (p20 = 24%, p80 = 41%). Vol spiked to nearly 200% in the July 2025 dislocation and has been mean-reverting ever since. The market is no longer pricing acute stress, but is still demanding above-average compensation for owning the name. A drop back toward the p20 line (24%) would itself be a constructive signal — it would say the post-crash uncertainty premium has been earned out.

7. Technical Scorecard

Net score: +1 (cautiously bullish on a 3-to-6 month horizon). The trend has flipped, near-term momentum is hot, and the volatility shock is in the rear-view. What is missing is volume confirmation and a multi-year base — the 1-year and 3-year returns still anchor the long-horizon view firmly negative, and the bounce is being delivered on lighter and lighter tape.

The two levels that change this view:

• Above $48 — clears the post-crash consolidation ceiling and approaches the median sell-side target of $45. A weekly close above $48 with rising volume would convert "bounce" into "trend reversal" and align the price action with the Numbers tab's Marketplace-MLR-improvement scenario.
• Below $36 — loses the 200-day SMA. A daily close below $36 invalidates the January golden cross, recouples price action with the bear thesis on the cost line, and reopens the path back toward the $25 July 2025 low.

The technical setup, in one line: a sub-$25 stock priced at $42 after a vertical bounce — either it earns the trend reversal by clearing $48, or it gives back the gains the moment the 200-day breaks.